Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adagrasib in Combination With Cetuximab and Irinotecan in KRAS G12C Colorectal Cancer
NCT05722327Phase 1Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2023
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of adagrasib in colorectal cancer (CRC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of Adverse Events at 1 year. Started Dec 2023; status: active, not recruiting.
02
Drugs
adagrasib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT05722327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05722327.